Skip to main content
SpringerLink
Log in

Recent Developments in the Management of Orbital and Periocular Neoplasms

  • Chapter
  • First Online:
Global Perspectives in Ocular Oncology

  • 235 Accesses

Abstract

Orbital and periorbital malignancies account for a significant proportion of cancers in ophthalmic oncology, encompass a wide variety of histologies, and are more frequently encountered than intraocular tumors. In this chapter, we focus on the major types of orbital and periorbital cancers: lymphoma, melanoma, squamous cell carcinoma, basal cell carcinoma, and lacrimal gland tumors. Treatments are often multidisciplinary and aim to eliminate cancer with the least ocular morbidity possible. Surgery remains the mainstay treatment; however, newer medical treatments such as immunotherapy and targeted biologic treatments have been a welcome addition for locally advanced and metastatic disease. For low-grade ocular adnexal lymphoma, significantly lower doses of radiation compared with “standard dose” have demonstrated good efficacy, lowering the morbidity and cost associated with radiotherapy. Finally, perspectives on sentinel node biopsy for detection of early microscopic disease associated with eyelid cancers and multidisciplinary eye-sparing treatments for lacrimal gland carcinomas will be highlighted.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Esmaeli B, Wang B, Deavers M, Gillenwater A, Goepfert H, Diaz E, Eicher S. Prognostic factors for survival in malignant melanoma of the eyelid skin. Ophthalmic Plast Reconstr Surg. 2000;16(4):250–7.

    Article  CAS  Google Scholar 

  2. Wong JR, Nanji AA, Galor A, Karp CL. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014;9(3):185–204.

    Article  CAS  Google Scholar 

  3. Mancera N, Smalley KS, Margo CE. Melanoma of the eyelid and periocular skin: histopathologic classification and molecular pathology. Surv Ophthalmol. 2019;64(3):272–88.

    Article  Google Scholar 

  4. Yin VT, Warneke CL, Merritt HA, Esmaeli B. Number of excisions required to obtain clear surgical margins and prognostic value of AJCC T category for patients with eyelid melanoma. Br J Ophthalmol. 2014;98(12):1681–5.

    Article  Google Scholar 

  5. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214(4):491.

    Article  CAS  Google Scholar 

  6. Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011;104(4):341–53.

    Article  Google Scholar 

  7. Esmaeli B, Eicher S, Popp J, Delpassand E, Prieto VG, Gershenwald JE. Sentinel lymph node biopsy for conjunctival melanoma. Ophthalmic Plast Reconstr Surg. 2001;17(6):436–42.

    Article  CAS  Google Scholar 

  8. Pfeiffer ML, Ozgur OK, Myers JN, Peng A, Ning J, Zafereo ME, Thakar S, Thuro B, Prieto VG, Ross MI, Esmaeli B. Sentinel lymph node biopsy for ocular adnexal melanoma. Acta Ophthalmol. 2017;95(4):e323–8.

    Article  CAS  Google Scholar 

  9. Cohen VM, Tsimpida M, Hungerford JL, Jan H, Cerio R, Moir G. Prospective study of sentinel lymph node biopsy for conjunctival melanoma. Br J Ophthalmol. 2013;97(12):1525–9.

    Article  Google Scholar 

  10. Freitag SK, Aakalu VK, Tao JP, Wladis EJ, Foster JA, Sobel RK, Yen MT. Sentinel lymph node biopsy for eyelid and conjunctival malignancy: a report by the American Academy of Ophthalmology. Ophthalmology. 2020;127(12):1757–65.

    Article  Google Scholar 

  11. Herrscher H, Robert C. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. Curr Opin Oncol. 2020;32(2):106–13.

    Article  CAS  Google Scholar 

  12. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

    Article  CAS  Google Scholar 

  13. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  CAS  Google Scholar 

  14. US-FDAFDA labeling information—ZELBORAF.2020FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Accessed 14 May 2021.

  15. US-FDAFDA labeling information—TAFINLAR.2020FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Accessed 14 May 2021.

  16. Greco A, Safi D, Swami U, Ginader T, Milhem M, Zakharia Y. Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review. Cancers. 2019;11(12):1950.

    Article  CAS  Google Scholar 

  17. Pahlitzsch M, Bertelmann E, Mai C. Conjunctival melanoma and BRAF inhibitor therapy. J Clin Exp Ophthalmol. 2014;5(1):322.

    Article  Google Scholar 

  18. Maleka A, Åström G, Byström P, Ullenhag GJ. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. BMC Cancer. 2016;16(1):1–5.

    Article  Google Scholar 

  19. Glass LR, Lawrence DP, Jakobiec FA, Freitag SK. Conjunctival melanoma responsive to combined systemic BRAF/MEK inhibitors. Ophthalmic Plast Reconstr Surg. 2017;33(5):e114–6.

    Article  Google Scholar 

  20. Rossi E, Maiorano BA, Pagliara MM, Sammarco MG, Dosa T, Martini M, Rindi G, Bria E, Blasi MA, Tortora G, Schinzari G. Dabrafenib and trametinib in BRAF mutant metastatic conjunctival melanoma. Front Oncol. 2019;9:232.

    Article  Google Scholar 

  21. Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.

    Article  CAS  Google Scholar 

  22. Mackin AG, Pecen PE, Dinsmore AL, Patnaik JL, Gonzalez R, Robinson WA, Palestine AG. Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019;29(5):522–6.

    Article  CAS  Google Scholar 

  23. Liu M, Yang X, Liu J, Zhao B, Cai W, Li Y, Hu D. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8(19):32258.

    Article  Google Scholar 

  24. Peng L, Wang Y, Hong Y, Ye X, Shi P, Zhang J, Zhao Q. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget. 2017;8(47):83280.

    Article  Google Scholar 

  25. Yin VT, Wiraszka TA, Tetzlaff M, Curry JL, Esmaeli B. Cutaneous eyelid neoplasms as a toxicity of vemurafenib therapy. Ophthalmic Plast Reconstr Surg. 2015;31(4):e112–5.

    Article  Google Scholar 

  26. US-FDAFDA labeling information—YERVOY.2020FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s074lbl.pdf. Accessed 10 March 2021.

  27. US-FDAFDA labeling information—OPDIVO.2019FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s024lbl.pdf. Accessed 10 March 2021.

  28. US-FDAFDA labeling information—KEYTRUDA.2021FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s015lbl.pdf. Accessed 10 March 2021.

  29. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889.

    Article  CAS  Google Scholar 

  30. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  Google Scholar 

  31. Barone A, Hazarika M, Theoret MR, Mishra-Kalyani P, Chen H, He K, Sridhara R, Subramaniam S, Pfuma E, Wang Y, Li H. FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma. Clin Cancer Res. 2017;23(19):5661–5.

    Article  CAS  Google Scholar 

  32. Beaver JA, Theoret MR, Mushti S, He K, Libeg M, Goldberg K, Sridhara R, McKee AE, Keegan P, Pazdur R. FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Clin Cancer Res. 2017;23(14):3479–83.

    Article  CAS  Google Scholar 

  33. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

    Article  Google Scholar 

  34. Sagiv O, Thakar SD, Kandl TJ, Ford J, Sniegowski MC, Hwu WJ, Esmaeli B. Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma. JAMA Ophthalmol. 2018;136(11):1236–41.

    Article  Google Scholar 

  35. Finger PT, Pavlick AC. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series. J Immunother Cancer. 2019;7(1):1–7.

    Article  Google Scholar 

  36. Kini A, Fu R, Compton C, Miller DM, Ramasubramanian A. Pembrolizumab for recurrent conjunctival melanoma. JAMA Ophthalmol. 2017;135(8):891–2.

    Article  Google Scholar 

  37. Chaves LJ, Huth B, Augsburger JJ, Correa ZM. Eye-sparing treatment for diffuse invasive conjunctival melanoma. Ocular Oncol Pathol. 2018;4(4):261–6.

    Article  Google Scholar 

  38. Pinto Torres S, André T, Gouveia E, Costa L, Passos MJ. Systemic treatment of metastatic conjunctival melanoma. Case Rep Oncol Med. 2017;2017:4623964.

    Google Scholar 

  39. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8.

    Article  Google Scholar 

  40. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80.

    Article  CAS  Google Scholar 

  41. Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019;20(1):e54–64.

    Article  CAS  Google Scholar 

  42. Reifler DM, Hornblass A. Squamous cell carcinoma of the eyelid. Surv Ophthalmol. 1986;30(6):349–65.

    Article  CAS  Google Scholar 

  43. Tanenbaum M, Grove AS Jr, McCord CD Jr. Eyelid tumors: diagnosis and management. Oculoplastic Surgery. 3rd ed. New York: Raven Press Ltd.; 1995. p. 145–74.

    Google Scholar 

  44. Wawrzynski J, Tudge I, Fitzgerald E, Collin R, Desai P, Emeriewen K, Saleh GM. Report on the incidence of squamous cell carcinomas affecting the eyelids in England over a 15-year period (2000–2014). Br J Ophthalmol. 2018;102(10):1358–61.

    Article  Google Scholar 

  45. Nasser QJ, Roth KG, Warneke CL, Yin VT, El Sawy T, Esmaeli B. Impact of AJCC ‘T’designation on risk of regional lymph node metastasis in patients with squamous carcinoma of the eyelid. Br J Ophthalmol. 2014;98(4):498–501.

    Article  Google Scholar 

  46. Sun MT, Andrew NH, O’Donnell B, McNab A, Huilgol SC, Selva D. Periocular squamous cell carcinoma: TNM staging and recurrence. Ophthalmology. 2015;122(7):1512–6.

    Article  Google Scholar 

  47. Ford J, Thakar S, Thuro B, Esmaeli B. Prognostic value of the staging system for eyelid tumors in the 7th edition of the American Joint Committee on Cancer Staging Manual. Ophthal Plast Reconstr Surg. 2017;33(5):317–24.

    Article  Google Scholar 

  48. Faustina M, Diba R, Ahmadi MA, Gutstein BF, Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology. 2004;111(10):1930–2.

    Article  Google Scholar 

  49. Sullivan TJ. Squamous cell carcinoma of eyelid, periocular, and periorbital skin. Int Ophthalmol Clin. 2009;49(4):17–24.

    Article  Google Scholar 

  50. McCord CD Jr, Cavanagh HD. Microscopic features and biologic behavior of eyelid tumors. Ophthalmic Surg. 1980;11(10):671–81.

    Google Scholar 

  51. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–90.

    Article  CAS  Google Scholar 

  52. Xu S, Sagiv O, Rubin ML, Sa HS, Tetzlaff MT, Nagarajan P, Ning J, Esmaeli B. Validation study of the AJCC cancer staging manual, staging system for eyelid and periocular squamous cell carcinoma. JAMA Ophthalmol. 2019;137(5):537–42.

    Article  Google Scholar 

  53. Cook BE Jr, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001;108(11):2088–98.

    Article  Google Scholar 

  54. Yin VT, Merritt HA, Sniegowski M, Esmaeli B. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol. 2015;33(2):159–69.

    Article  CAS  Google Scholar 

  55. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2):S21–6.

    Article  Google Scholar 

  56. Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg. 2013;29(2):87–92.

    Article  Google Scholar 

  57. Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract. 2011;207(6):337–42.

    Article  CAS  Google Scholar 

  58. Moreira J, Tobias A, O’Brien MP, Agulnik M. Targeted therapy in head and neck cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies. Drugs. 2017;77(8):843–57.

    Article  CAS  Google Scholar 

  59. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.

    Article  CAS  Google Scholar 

  60. Acevedo-Henao CM, Valette G, Miglierini P, Lefur E, Pradier O. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity. Cancer/Radiothérapie. 2012;16(7):601–3.

    Article  CAS  Google Scholar 

  61. Shepler TR, Prieto VG, Diba R, Neuhaus RW, Shore JW, Esmaeli B. Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma. Ophthalmic Plast Reconstr Surg. 2006;22(2):113–5.

    Article  Google Scholar 

  62. El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli B. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012;130(12):1608–11.

    Article  Google Scholar 

  63. Gellrich FF, Hüning S, Beissert S, Eigentler T, Stockfleth E, Gutzmer R, Meier F. Medical treatment of advanced cutaneous squamous-cell carcinoma. J Eur Acad Dermatol Venereol. 2019;33:38–43.

    Article  Google Scholar 

  64. Bindiganavile SH, Bhat N, Lee AG, Gombos DS, Al-Zubidi N. Targeted cancer therapy and its ophthalmic side effects: a review. J Immunother Prec Oncol. 2021;4(1):6–15.

    Article  Google Scholar 

  65. Markham A, Duggan S. Cemiplimab: first global approval. Drugs. 2018;78(17):1841–6.

    Article  CAS  Google Scholar 

  66. Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, Pavlick AC, Carucci JA. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153(4):299–303.

    Article  Google Scholar 

  67. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang AL, Rabinowits G. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51.

    Article  CAS  Google Scholar 

  68. Migden MR, Khushalani NI, Chang AL, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294–305.

    Article  CAS  Google Scholar 

  69. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US).

  70. Konidaris G, Paul E, Kuznik A, Keeping S, Chen CI, Sasane M, Xu Y, Atsou K, Ayers D, Ruiz ES, Khushalani NI. Assessing the value of cemiplimab for adults with advanced cutaneous squamous cell carcinoma: a cost-effectiveness analysis. Value Health. 2021;24(3):377–87.

    Article  Google Scholar 

  71. Conger JR, Grob SR, Tao J. Massive periocular squamous cell carcinoma with response to pembrolizumab (Keytruda). Ophthalmic Plast Reconstr Surg. 2019;35(5):e127.

    Article  Google Scholar 

  72. Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106(4):746–50.

    Article  Google Scholar 

  73. Margo CE, Waltz K. Basal cell carcinoma of the eyelid and periocular skin. Surv Ophthalmol. 1993;38(2):169–92.

    Article  CAS  Google Scholar 

  74. Branson SV, McClintic E, Ozgur O, Esmaeli B, Yeatts RP. Orbitofacial metastatic basal cell carcinoma: report of 10 cases. Ophthal Plast Reconstr Surg. 2017;33(3):213–7.

    Article  Google Scholar 

  75. Savar A, Esmaeli B. Management of primary eyelid cancers. Ophthalmic oncology. Boston, MA: Springer; 2010. p. 113–25.

    Book  Google Scholar 

  76. Wong VA, Marshall JA, Whitehead KJ, Williamson RM, Sullivan TJ. Management of periocular basal cell carcinoma with modified en face frozen section controlled excision. Ophthalmic Plast Reconstr Surg. 2002;18(6):430–5.

    Article  Google Scholar 

  77. Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology. 2004;111(4):631–6.

    Article  Google Scholar 

  78. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180–8.

    Article  CAS  Google Scholar 

  79. Marigo V, Davey RA, Zuo Y, Cunningham JM, Tabin CJ. Biochemical evidence that patched is the Hedgehog receptor. Nature. 1996;384(6605):176–9.

    Article  CAS  Google Scholar 

  80. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–72.

    Article  Google Scholar 

  81. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502–11.

    Article  CAS  Google Scholar 

  82. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.

    Article  CAS  Google Scholar 

  83. Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli B. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160(2):220–7.

    Article  CAS  Google Scholar 

  84. Sagiv O, Nagarajan P, Ferrarotto R, Kandl TJ, Thakar SD, Glisson BS, Altan M, Esmaeli B. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2019;103(6):775–80.

    Article  Google Scholar 

  85. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–28.

    Article  CAS  Google Scholar 

  86. Hou X, Rokohl AC, Ortmann M, Heindl LM. Effective treatment of locally advanced periocular basal cell carcinoma with oral hedgehog pathway inhibitor? Graefes Arch Clin Exp Ophthalmol. 2020;258:2335–7.

    Article  Google Scholar 

  87. Chang AL, Tran DC, Cannon JG, Li S, Jeng M, Patel R, Van der Bokke L, Pague A, Brotherton R, Rieger KE, Satpathy AT. Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019;80(2):564–6.

    Article  Google Scholar 

  88. Fischer S, Ali OH, Jochum W, Kluckert T, Flatz L, Siano M. Anti-PD-1 therapy leads to near-complete remission in a patient with metastatic basal cell carcinoma. Oncol Res Treat. 2018;41(6):391–4.

    Article  CAS  Google Scholar 

  89. US-FDA. FDA labeling information—LIBTAYO. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf. Accessed 10 May 2021.

  90. Stratigos AJ, Sekulic A, Peris K, Bechter O, Kaatz M, Lewis KD, Basset-Seguin N, Chang AL, Dalle S, Orland AF, Licitra L. Primary analysis of phase 2 results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs). Head Neck. 2021;89:75.

    Google Scholar 

  91. Lewis K, Peris K, Sekulic A, Stratigos A, Dunn L, Eroglu Z, Chang AL, Migden M, Li S, Mohan K, Coates E. 428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs). J Immunother Cancer. 2021;(5)1.

    Google Scholar 

  92. Olsen TG, Holm F, Mikkelsen LH, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, Grossniklaus HE, Honavar SG, Khong JJ. Orbital lymphoma—an international multicenter retrospective study. Am J Ophthalmol. 2019;199:44–57.

    Article  Google Scholar 

  93. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

    Article  CAS  Google Scholar 

  94. Hindsø TG, Esmaeli B, Holm F, Mikkelsen LH, Rasmussen PK, Coupland SE, Finger PT, Graue GF, Grossniklaus HE, Honavar SG, Khong JJ. International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma. Br J Ophthalmol. 2020;104(3):357–62.

    Article  Google Scholar 

  95. Margo CE, Mulla ZD. Malignant tumors of the orbit: analysis of the Florida Cancer Registry. Ophthalmology. 1998;105(1):185–90.

    Article  CAS  Google Scholar 

  96. Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49(sup1):43–51.

    Article  CAS  Google Scholar 

  97. Sniegowski MC, Roberts D, Bakhoum M, Mc Laughlin P, Yin VT, Turturro F, Esmaeli B. Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventh edition staging guidelines. Br J Ophthalmol. 2014;98(9):1255–60.

    Article  Google Scholar 

  98. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH. Rates of positive findings on positron emission tomography and bone marrow biopsy in patients with ocular adnexal lymphoma. Ophthal Plast Reconstr Surg. 2017;33(5):355–60.

    Article  Google Scholar 

  99. Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, El-Sawy T, McLaughlin P, Bakhoum MF, Esmaeli B. Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma. 2014;55(5):1013–7.

    Article  CAS  Google Scholar 

  100. Kirkegaard MM, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, Grossniklaus HE, Honavar SG, Khong JJ, McKelvie PA, Mulay K. Conjunctival lymphoma—an international multicenter retrospective study. JAMA Ophthalmol. 2016;134(4):406–14.

    Article  Google Scholar 

  101. Svendsen FH, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, Grossniklaus HE, Honavar SG, Khong JJ, McKelvie PA, Mulay K. Lymphoma of the eyelid–an international multicenter retrospective study. Am J Ophthalmol. 2017;177:58–68.

    Article  Google Scholar 

  102. Bolek TW, Moyses HM, Marcus RB Jr, Gorden L III, Maiese RL, Almasri NM, Mendenhall NP. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys. 1999;44(1):31–6.

    Article  CAS  Google Scholar 

  103. Pelloski CE, Wilder RB, Ha CS, Hess MA, Cabanillas FF, Cox JD. Clinical stage IEA–IIEA orbital lymphomas: outcomes in the era of modern staging and treatment. Radiother Oncol. 2001;59(2):145–51.

    Article  CAS  Google Scholar 

  104. Stafford SL, Kozelsky TF, Garrity JA, Kurtin PJ, Leavitt JA, Martenson JA, Habermann TM. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol. 2001;59(2):139–44.

    Article  CAS  Google Scholar 

  105. Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006;108(5):1451–60.

    Article  CAS  Google Scholar 

  106. Pinnix CC, Dabaja BS, Milgrom SA, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017;39(6):1095–100.

    Article  Google Scholar 

  107. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  Google Scholar 

  108. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.

    Article  CAS  Google Scholar 

  109. Keating GM. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. BioDrugs. 2011;25(1):55–61.

    Article  Google Scholar 

  110. Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1(3):e104–11.

    Article  Google Scholar 

  111. von Holstein SL. Tumours of the lacrimal gland. Epidemiological, clinical and genetic characteristics. Doctoral dissertation. 2013.

    Google Scholar 

  112. Shields J, Shields C. Lacrimal gland primary epithelial tumors. In: Shields J, Shields C, editors. Eyelid, conjunctival, and orbital tumors: an atlas and text. Philadelphia: Lippincott Williams and Wilkins; 2011. p. 700–25.

    Google Scholar 

  113. Tom A, Bell D, Ford JR, Debnam JM, Guo Y, Frank SJ, Esmaeli B. Malignant mixed tumor (carcinoma ex pleomorphic adenoma) of the lacrimal gland. Ophthal Plast Reconstr Surg. 2020;36(5):497–502.

    Article  Google Scholar 

  114. Esmaeli B, Yin VT, Hanna EY, Kies MS, William WN Jr, Bell D, Frank SJ. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck. 2016;38(8):1258–62.

    Article  Google Scholar 

  115. Woo KI, Sagiv O, Han J, Frank SJ, Kim YD, Esmaeli B. Eye-preserving surgery followed by adjuvant radiotherapy for lacrimal gland carcinoma: outcomes in 37 patients. Ophthalmic Plast Reconstr Surg. 2018;34(6):570–4.

    Article  Google Scholar 

  116. Wolkow N, Jakobiec FA, Lee H. Long-term outcomes of globe-preserving surgery with proton beam radiation for adenoid cystic carcinoma of lacrimal gland. Am J Ophthalmol. 2019;201:84–5.

    Article  Google Scholar 

  117. Rose GE, Gore SK, Plowman NP. Cranio-orbital resection does not appear to improve survival of patients with lacrimal gland carcinoma. Ophthalmic Plast Reconstr Surg. 2019;35(1):77–84.

    Article  Google Scholar 

  118. Hung JY, Wei YH, Huang CH, Chen LW, Fuh CS, Liao SL. Survival outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland. Jpn J Ophthalmol. 2019;63(4):344–51.

    Article  Google Scholar 

  119. Han J, Kim YD, Woo KI, Sobti D. Long-term outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland. Ophthal Plast Reconstr Surg. 2018;34(1):74–8.

    Article  Google Scholar 

  120. Bonavolontà P, Esmaeli B, Donna P, Tranfa F, Iuliano A, Abbate V, Fossataro F, Attanasi F, Bonavolontà G. Outcomes after eye-sparing surgery vs orbital exenteration in patients with lacrimal gland carcinoma. Head Neck. 2020;42(5):988–93.

    Article  Google Scholar 

  121. Ford JR, Rubin ML, Frank SJ, Ning J, Debnam JM, Bell D, El-Naggar A, Ferrarotto R, Esmaeli B. Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma. Br J Ophthalmol. 2021;105(6):768–74.

    Article  Google Scholar 

  122. Tse DT, Kossler AL, Feuer WJ, Benedetto PW. Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2013;120(7):1313–23.

    Article  Google Scholar 

  123. Fellman M, Carter K, Call CB, Esmaeli B. Disease recurrence after intraarterial chemotherapy in 2 patients with adenoid cystic carcinoma of lacrimal gland. Can J Ophthalmol. 2013;48(2):e17–8.

    Article  Google Scholar 

  124. Jang SY, Kim DJ, Kim CY, Wu CZ, Yoon JS, Lee SY. Neoadjuvant intra-arterial chemotherapy in patients with primary lacrimal adenoid cystic carcinoma. Cancer Imaging. 2014;14(1):1–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jeremy A. Goldfarb & Bita Esmaeli

Authors
  1. Jeremy A. Goldfarb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bita Esmaeli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bita Esmaeli .

Editor information

Editors and Affiliations

  1. Ocular Oncology Service Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India

    Bhavna V. Chawla

  2. Retina Service Massachusetts Eye and Ear Harvard Medical School, Boston, MA, USA

    Mary E. Aronow

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Goldfarb, J.A., Esmaeli, B. (2022). Recent Developments in the Management of Orbital and Periocular Neoplasms. In: Chawla, B.V., Aronow, M.E. (eds) Global Perspectives in Ocular Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-08250-4_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-08250-4_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-08249-8

  • Online ISBN: 978-3-031-08250-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation